[Limited 5-fluorouracil-induced systemic scleroderma].
Benomar
S
S
Boutayeb
S
S
Benzekri
L
L
Senouci
K
K
Errihani
H
H
Hassam
B
B
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003082:Colectomy; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D009543:Nifedipine / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D002121:Calcium Channel Blockers; D009543:Nifedipine; D005472:Fluorouracil